GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Psyence Biomedical Ltd (NAS:PBM) » Definitions » ROC (Joel Greenblatt) %

Psyence Biomedical (Psyence Biomedical) ROC (Joel Greenblatt) %

: 0.00% (As of Mar. 2023)
View and export this data going back to 2024. Start your Free Trial

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Psyence Biomedical's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2023 was 0.00%.

The historical rank and industry rank for Psyence Biomedical's ROC (Joel Greenblatt) % or its related term are showing as below:

PBM's ROC (Joel Greenblatt) % is not ranked *
in the Biotechnology industry.
Industry Median: -339.84
* Ranked among companies with meaningful ROC (Joel Greenblatt) % only.

Psyence Biomedical's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 0.00% per year.


Psyence Biomedical ROC (Joel Greenblatt) % Historical Data

The historical data trend for Psyence Biomedical's ROC (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Psyence Biomedical Annual Data
Trend Mar21 Mar22 Mar23
ROC (Joel Greenblatt) %
- - -

Psyence Biomedical Semi-Annual Data
Mar21 Mar22 Mar23
ROC (Joel Greenblatt) % - - -

Competitive Comparison

For the Biotechnology subindustry, Psyence Biomedical's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Psyence Biomedical ROC (Joel Greenblatt) % Distribution

For the Biotechnology industry and Healthcare sector, Psyence Biomedical's ROC (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where Psyence Biomedical's ROC (Joel Greenblatt) % falls into.



Psyence Biomedical ROC (Joel Greenblatt) % Calculation

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:

ROC (Joel Greenblatt) %=EBIT/Average of (Net fixed Assets + Net Working Capital)

EBIT stands for Earnings Before Interest and Taxes.

Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.

GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.

Working Capital(Q: Mar. 2022 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 0.04) - (0.13 + 0 + 0)
=-0.09

Working Capital(Q: Mar. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 0.109) - (1.771 + 0 + 0)
=-1.662

When net working capital is negative, 0 is used.

So ROC (Joel Greenblatt) % of Psyence Biomedical for the quarter that ended in Mar. 2023 can be restated as:

ROC (Joel Greenblatt) %(Q: Mar. 2023 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Mar. 2022  Q: Mar. 2023
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-3.125/( ( (0 + max(-0.09, 0)) + (0 + max(-1.662, 0)) )/ 1 )
=-3.125/( ( 0 + 0 )/ 1 )
=-3.125/0
= %

Note: The EBIT data used here is one times the annual (Mar. 2023) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Psyence Biomedical  (NAS:PBM) ROC (Joel Greenblatt) % Explanation

The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.

Joel Greenblatt uses his definition of Return on Capital and Earnings Yield (Joel Greenblatt) % to rank companies.


Psyence Biomedical ROC (Joel Greenblatt) % Related Terms

Thank you for viewing the detailed overview of Psyence Biomedical's ROC (Joel Greenblatt) % provided by GuruFocus.com. Please click on the following links to see related term pages.


Psyence Biomedical (Psyence Biomedical) Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
121 Richmond Street West, Penthouse Suite 1300, Toronto, ON, CAN, M5H 2K1
Psyence Biomedical Ltd is a life science biotechnology company pioneering the use of natural psychedelics in mental health and wellbeing. It develops natural psilocybin products for the healing of psychological trauma and its mental health consequences in the context of palliative care. The company has commenced the clinical trial process to evaluate the safety and efficacy of its product candidates. It cultivates natural psilocybin mushrooms at its federally licensed ISO22000 facility in Southern Africa. This product is produced for export to its partners across the world to be processed into a standardized encapsulated product.

Psyence Biomedical (Psyence Biomedical) Headlines